Ginkgo Bioworks Holdings, Inc. (DNA) Profit Margins
Over the twelve months to 2026-06-30, Ginkgo Bioworks Holdings, Inc. (DNA) had operating margin -259.9%, net margin -260.0%, free cash flow margin -156.3%, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
DNAGinkgo Bioworks Holdings, Inc.Follow DNA — free
—
Price chart with a free account
- Market cap
- 672.7M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 5 Nov, in 12 days
| Line | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|
| Gross margin | 58.7% | 57.3% | 78.5% | 80.4% | 72.4% | — | |
| Operating margin | -582.6% | -462.4% | -343.8% | -246.5% | -185.3% | -259.9% | |
| Net margin | -583.1% | -440.6% | -355.1% | -240.9% | -183.8% | -260.0% | |
| FCF margin | -98.9% | -63.7% | -133.7% | -168.3% | -105.0% | -156.3% |
USD billions · SEC XBRL
Ginkgo Bioworks Holdings, Inc. — questions
- What is Ginkgo Bioworks Holdings, Inc.'s operating margin?
- -259.9% over the twelve months to 2026-06-30.
- What is Ginkgo Bioworks Holdings, Inc.'s net profit margin?
- -260.0% over the twelve months to 2026-06-30.
Every figure on this page comes from Ginkgo Bioworks Holdings, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.